Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem

blonca9
Apr 9
1 min read

Brad Sitko describes how XOMA is able to do smaller deals than other larger investors in this space, and he gives examples of investments they have made. Plus how to help with the "zombie biotech" problem in some corners of the sector.

Brought to you by:

Recent Posts

See All

ASH 2025: Orca Bio has an April 6th PDUFA date from FDA for its cell therapy product, Orca-T, that aims to solve the problem of treatment-related toxicities that come with stem cell transplants

ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cel. Plus, the future of dual antigen and in vivo CAR-Ts.

ASH 2025: Von Willebrand disease is the most common bleeding disorder, though many people have never heard of it. Star Therapeutics is working on a solution that is already in phase 3

Jones Healthcare & Technology Innovation Conference: The CIO of XOMA Royalty describes the inner workings of the royalty business, and also how to help with biotech's negative enterprise problem

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight